Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 25:16:451-465.
doi: 10.2147/COPD.S281957. eCollection 2021.

Characteristics, Management and In-Hospital Clinical Outcomes Among Inpatients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in China: Results from the Phase I Data of ACURE Study

Chen Liang  1 , Xihua Mao  1 , Hongtao Niu  2   3   4 , Ke Huang  2   3   4 , Fen Dong  2   3   4   5 , Yahong Chen  6 , Kewu Huang  7   8 , Qingyuan Zhan  2   3   4 , Yin Huang  1 , Yaowen Zhang  1 , Ting Yang  2   3   4 , Chen Wang  2   3   4   9
Affiliations
Review

Characteristics, Management and In-Hospital Clinical Outcomes Among Inpatients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in China: Results from the Phase I Data of ACURE Study

Chen Liang et al. Int J Chron Obstruct Pulmon Dis. .

Abstract

Purpose: The study aimed to give a comprehensive overview of characteristics and evaluate in-hospital clinical outcomes among hospitalized acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients in China using data from the AECOPD inpatient registry (ACURE).

Patients and methods: The ACURE is an ongoing, national, multicenter, observational registry. Participants enrolled during phase I stage (1st September 2017 to 25th February 2020) of ACURE with confirmed AECOPD diagnoses were studied. Descriptive analyses were conducted to describe features and occurrences of in-hospital clinical outcomes of AECOPD inpatients in real-world China.

Results: A total of 5334 AECOPD inpatients from 163 sites in 28 provinces or province-level municipalities were included. Among all participants, 78.8% were males and the median age was 69.0 [interquartile range (IQR): 63.0-76.0] years. The proportions of current and former smokers were 23.6% and 44.2%, respectively. The median age at COPD diagnosis was 64.0 (IQR: 57.0-71.0) years and 88.7% participants demonstrated at least one comorbidity. During stable period, only 56.9% subjects received pharmacological therapies and the influenza vaccination rate was 2.9%. During hospitalization, 99.5% subjects received pharmacological treatments and antibiotics were prescribed to 90.9% participants. The all-cause in-hospital mortality was 0.1% and no significant difference was found across hospital categories.

Conclusion: Clinical features of Chinese AECOPD inpatients were different from those of other populations. In real-world China, the clinical management during stable period was unsatisfied, whereas therapy during hospitalization was effective regarding in-hospital clinical outcomes regardless of hospital category.

Keywords: demography; disease management; hospital mortality; public health; registries; therapeutics.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work. The ACURE study is funded by the Chinese Academy of Medical Sciences, basic scientific research business fee fund of central level public welfare scientific research institutes-Research on Prevention and Control System of Chronic Airway Diseases (grant number 2019TX320005), National Key R&D Program of China (grant number 2016YFC1303900, 2016YFC1304300), CAMS Innovation Fund for Medical Sciences (CIFMS) (grant number 2018-I2M-1-001). The funders of the study had no role in study design, data collection and management, data analysis, data interpretation, writing of the manuscript, and the decision to submit the manuscript for publication.

Figures

Figure 1
Figure 1
Flow Chart of Obtaining the Study Population.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2020report). Global Initiative for Chronic Obstructive Lung Disease (GOLD) Committees. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-0.... Accessed April28, 2020.
    1. Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/S2213-2600(17)30293-X - DOI - PMC - PubMed
    1. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–1717. doi:10.1016/S0140-6736(18)30841-9 - DOI - PubMed
    1. Fang X, Wang X, Bai C. COPD in China: the burden and importance of proper management. Chest. 2011;139(4):920–929. doi:10.1378/chest.10-1393 - DOI - PMC - PubMed
    1. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2017 report). Global initiative for Chronic Obstructive Lung Disease (GOLD) Committees. .https://goldcopd.org/wp-content/uploads/2017/02/wms-GOLD-2017-FINAL.pdf. Accessed July7, 2020. - PubMed